Article
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
British journal of cancer - 26 Sept 2017
Li Meng, Yang Jingyu, Zhou Wenlong, Ren Yong, Wang Xiaoxuan, Chen Huiping, Zhang Jingyuan, Chen Junli, Sun Yuhong, Cui Lijuan, Liu Xing, Wang Lihui, Wu Chunfu
Abstract excerpt
BACKGROUND: Tyrosine kinase inhibitors (TKIs) have demonstrated clinical benefits in the treatment of several tumour types. However, the emergence of TKI resistance restricts the therapeutic effect. This study uses non-small cell lung cancer (NSCLC) to explore the mechanisms contributing to TKI resistance in tumours. METHODS: Biological phenotypes and RNA microarray expression data were analysed in NSCLC cells...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.